| Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation | Erden ATİLLA,Selami K. TOPRAK,Taner DEMİRER | 1–9 |
| Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia | Jing HUANG,Leyan WANG,Lu CHEN,He QUN,Xu YAJİNG,Chen FANGPİNG,Zhao XİELAN | 10–15 |
| Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study | Mehmet ÖZEN,Celalettin ÜSTÜN,Bengi ÖZTÜRK,PERVİN TOPÇUOĞLU,Mutlu ARAT,Mehmet GÜNDÜZ,Erden ATİLLA,Gülşen BOLAT,ÖNDER ARSLAN,TANER DEMİRER,HAMDİ AKAN,OSMAN İLHAN,MERAL BEKSAÇ,GÜNHAN GÜRMAN,MUHİT ÖZCAN | 16–26 |
| Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms | Nur SOYER,İbrahim C. HAZNEDAROĞLU,Melda CÖMERT,Demet ÇEKDEMİR,Mehmet YILMAZ,ALİ ÜNAL,GÜLSÜM AKGÜN ÇAĞLIYAN,OKTAY BİLGİR,OSMAN İLHAN,Füsun ÖZDEMİRKIRAN,EMİN KAYA,FAHRİ ŞAHİN,FİLİZ VURAL,GÜRAY SAYDAM | 27–33 |
| TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases | İBRAHİM KULAÇ,Çetin DEMİR,YAHYA BÜYÜKAŞIK,MUSTAFA TEZER KUTLUK,AYŞEGÜL ÜNER | 34–39 |
| Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature | Cengiz BAYRAM,HÜSNİYE NEŞE YARALI,Ali FETTAH,Fatma DEMİREL,Betül TAVİL,Abdurrahman KARA,Bahattin TUNÇ | 40–45 |
| FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center | Şebnem Yılmaz BENGOA,EDA ATASEVEN,Deniz KIZMAZOĞLU,Fatma Demir YENİGÜRBÜZ,Melek ERDEM,HALE ÖREN | 46–51 |
| Red Blood Cell Transtusions in Greece: Results of Survey of Red Blood Cell Use in 2013 | serena VALSAMİ | 52–58 |
| The Clinical Significance of Schistocytes: A Prospective Evaluation of the International Council for Standardization in Hematology Schistocyte Guidelines | Elise SCHAPKAİTZ,Michael Halefom MEZGEBE | 59–63 |
|